This is a preview of subscription content
Access options
Subscription info for Chinese customers
We have a dedicated website for our Chinese customers. Please go to naturechina.com to subscribe to this journal.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.
References
Original article
Janjigian, Y. Y. et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 600, 727–730 (2021)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hindson, J. KEYNOTE-811: pembrolizumab in advanced HER2+ gastric cancer. Nat Rev Gastroenterol Hepatol 19, 79 (2022). https://doi.org/10.1038/s41575-022-00577-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-022-00577-y